Matthew Budoff, MD, Will Present the Analyses at the European Society of Cardiology (ESC) Preventive Cardiology 2021
Investigator(s):
Matthew Budoff, MD
LOS ANGELES (April 17, 2021) — Today, The Lundquist Institute announced that Matthew Budoff, MD, Director of Cardiovascular CT at the Institute and Professor of Medicine at the David Geffen School of Medicine at UCLA, will present further analyses from the Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: EVAPORATE Trial as Late- Breaking Science at European Society of Cardiology (ESC) Preventive Cardiology 2021, the Annual Congress of the European Association of Preventive Cardiology.
For Critically Ill Patients with Advanced Medical Illnesses and Poor Prognoses, Overuse of Invasive ICU Treatment May Prolong Suffering
Investigator(s):
Dong Chang, MD
LOS ANGELES (April 13, 2021) — The Lundquist Institute (TLI) Investigator Dong W. Chang, MD, and his colleagues’ study on critically ill patients and ICU treatments was published in JAMA Internal Medicine. The study – “Evaluation of Time-Limited Trials Among Critically Ill Patients with Advanced Medical Illnesses and Reduction of Nonbeneficial ICU Treatments” – found that training physicians to communicate with family members of critically ill patients using a structured approach, which promotes shared decision-making, improved the quality of family meetings.
Bill & Melinda Gates Medical Research Institute To Develop Formulation
-Agreement advances evolution of synthetic lung surfactants to treat respiratory distress Syndrome in premature infants in Low- and Middle-Income Countries-
Investigator(s):
Frans Walther, MD, PhD, FAAP
LOS ANGELES — The Lundquist Institute (TLI) and The Bill & Melinda Gates Medical Research Institute (Gates MRI) executed a license agreement for TLI intellectual property covering a synthetic lung surfactant formulation to be developed for respiratory distress syndrome (RDS) for premature infants in Low- and Middle-Income countries (LMIC). TLI already maintains patents on this invention in the United States, Canada and Europe.
The Lundquist Institute researchers discovered a natural compound that exhibits almost ideal male contraceptive effects in pre-clinical studies
Investigator(s):
Wei Yan, MD, PhD
LOS ANGELES — In a new paper published by Nature Communications, The Lundquist Institute (TLI) Investigator Wei Yan, MD, PhD, and his research colleagues spell out an innovative strategy that has led to the discovery of a natural compound as a safe, effective and reversible male contraceptive agent in pre-clinical animal models. Despite tremendous efforts over the past decades, the progress in developing non-hormonal male contraceptives has been very limited.
The grant will fund clinical trials to study the efficacy of psilocybin in treating the emotional suffering associated with terminal medical illness
Investigator(s):
Charles Grob, MD
LOS ANGELES — The Lundquist Institute has received a $1.75 million grant from the Steven & Alexandra Cohen Foundation to fund a multi-site clinical trial to evaluate the efficacy and safety of the compound psilocybin in individuals with severe psychological distress associated with a terminal medical illness. The grant will also support education and outreach programs related to the use of psilocybin within the field of palliative care.
Amgen Golden Ticket Winners to Receive Lab Space, Mentoring and Other Benefits
Investigator(s):
The Lundquist Institute
THOUSAND OAKS, Calif. – Amgen (NASDAQ:AMGN) today announced a three-year, Golden Ticket sponsorship of the BioLabs LA at The Lundquist Institute (TLI) life sciences co-working space to accelerate the development of new therapies, medical devices, and diagnostics to advance and improve human health. The BioLabs at TLI shared laboratory space was created to help high-potential life science and biotech startups overcome key obstacles for many early stage organizations, including: access to laboratory infrastructure, programming, and business development mentorship.
Ashraf S. Ibrahim, PhD, Lead Author, on publication in the world’s No. 1 Scientific Journal for Microbiology
Investigator(s):
Ashraf Ibrahim, PhD
LOS ANGELES — Today Nature Microbiology publishes The Lundquist Institute Investigator Dr. Ashraf Ibrahim and his co-authors’ paper, “Mucoricin is a ricin-like toxin that is critical for the pathogenesis of mucormycosis.”
In a Year Dominated by the Global COVID Pandemic, The Institute Kept Moving Forward
Investigator(s):
The Lundquist Institute
LOS ANGELES — The Lundquist Institute, a world leader in biomedical research, today released its 2020 Year in Review video. 2020 was an unparalleled year and given the challenge of working against the backdrop of the global COVID pandemic, the Institute had one of its most outstanding years ever.
California Institute for Regenerative Medicine (CIRM) Funds New Research on Nanotechnology for Stem Cell Implantation and Diabetes Treatment
Investigator(s):
Eiji Yoshihara, PhD
LOS ANGELES — Two junior Investigators at the The Lundquist Institute, Dr. Eiji Yoshihara and Dr. Lina R. Nih, have received a Quest Award from the California Institute for Regenerative Medicine (CIRM). The Quest Award is for discovery research and aims to promote promising new technologies that could be translated for broad use and improved patient care.
First phase of plan includes up to 250,000 square feet of lab, manufacturing and office space
Investigator(s):
The Lundquist Institute
LOS ANGELES – The Lundquist Institute received unanimous approval from the Los Angeles County Board of Supervisors to begin development of a 15-acre biotech park, which will serve as a hub and catalyst for the region’s rapidly-developing bioscience industry.